New York, NY (PRWEB) November 04, 2013
The medication safety advocates at DrugNews.net are announcing the launch of a new resource site for patients taking the antipsychotic drug Risperdal. Information will be available on studies into the drug’s side effects, the issuance of safety alerts, as well as legal news for any injury claims.
DrugNews is a free resource for those using popular prescription drugs or medical devices. With updates on the latest safety alerts, recalls, studies and legal news, patients can avoid potential dangers, see if others are experiencing similar side effects and decide if they need legal advice.
Risperdal is an atypical antipsychotic drug from Johnson & Johnson subsidiary Janssen Pharmaceuticals approved to treat schizophrenia, bipolar disorder and autism. However, the company has been accused of promoting it for unapproved treatments in hundreds of thousands of children*.
The resource center has added studies linking the drug to gynecomastia, or abnormal breast growth in children and adult males that can be accompanied by milk production**. As the condition is non-reversible, it often requires surgery to correct.
Also, a study from Vanderbilt University published this year found that antipsychotics like Risperdal may triple the risk of type-2 diabetes in children***.
DrugNews has also learned that Janssen has already paid settlements to patients filing a Risperdal lawsuit alleging they needed surgery after the drug caused abnormal breast growth****.
Anyone affected by diabetes or abnormal breast growth after taking Risperdal is urged to visit DrugNews.net or speak with a lawyer about their legal options. However, due to the specialized nature of drug injury cases, DrugNews only recommends lawyers who have already handled Risperdal lawsuits.
Visit http://www.DrugNews.net today for more information on the research, side effects and litigation news related to Risperdal and other drugs, or to speak with a lawyer.
*Bloomberg, 7/20/12; bloomberg.com/news/2012-07-20/j-j-files-appeal-of-1-2-billion-arkansas-risperdal-ruling.html
**Cedars-Sinai Division of Endocrinology, Sept. 2012; ncbi.nlm.nih.gov/pubmed/22862307
***Vanderbilt University Medical Center, 8/22/13; news.vanderbilt.edu/2013/08/antipsychotic-drug-use-in-children-for-moodbehavior-disorders-increases-type-2-diabetes-risk/
****Bloomberg, 9/10/12; bloomberg.com/news/2012-09-10/j-j-settles-risperdal-lawsuit-on-opening-day-of-trial.html; Banks v. Janssen Pharmaceuticals, Philadelphia Court of Common Pleas, January Term 2010, No. 00618